The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

(Reuters) - Schneider Electric said on Tuesday it plans to invest over $700 million in its U.S. operations over the next two ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Asia Market Update: Mixed Asian equities in directionless start to week; USD/JPY threatens ¥150; KR PM Han returns as acting-Pres; Focus on UK, DE, EU, US Mar S&P PMIs.

U.S. Senator Steve Daines is visiting Beijing as the U.S. and China swap tariff threats and harsh words over each others’ ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.